Cyclosporine-induced hypertension after transplantation

Stephen C Textor, V. J. Canzanello, Sandra J Taler, D. J. Wilson, L. L. Schwartz, J. E. Augustine, J. M. Raymer, J. C. Romero, R. H. Wiesner, R. A F Krom, John C Jr. Burnett

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Objective: To describe the features and mechanisms of posttransplantation hypertension and suggest appropriate management of the disorder. Design: We review our own experience and reports from the literature on hypertension in cyclosporine A (CSA)-treated transplant recipients. Results: Soon after immunosuppression with CSA and corticosteroids, hypertension develops in most patients who undergo transplantation. The blood pressure increases, which are usually moderate, occur universally because of increased peripheral vascular resistance. Disturbances in circadian patterns of blood pressure lead to loss of the normal nocturnal decline, a feature that magnifies hypertensive target effects. Changes in blood pressure sometimes are severe and associated with rapidly developing target injury, including intracranial hemorrhage, left ventricular hypertrophy, and microangiopathic hemolysis. The complex mechanisms that underlie this disorder include alterations in vascular reactivity that cause widespread vasoconstriction. Vascular effects in the kidney lead to reduced glomerular filtration and impaired sodium excretion. Many of these changes affect local regulation of vascular tone, including stimulation of endothelin and suppression of vasodilating prostaglandins. Effective therapy includes use of vasodilating agents, often calcium channel blocking drugs. Caution must be exercised to avoid interfering with the disposition of CSA or aggravating adverse effects relative to kidney and electrolyte homeostasis. Conclusion: Recognition and treatment of CSA- induced hypertension and vascular injury are important elements in managing the transplant recipient.

Original languageEnglish (US)
Pages (from-to)1182-1193
Number of pages12
JournalMayo Clinic Proceedings
Volume69
Issue number12
StatePublished - 1994

Fingerprint

Cyclosporine
Transplantation
Hypertension
Blood Vessels
Blood Pressure
Vascular Resistance
Kidney
Intracranial Hemorrhages
Vascular System Injuries
Endothelins
Calcium Channel Blockers
Left Ventricular Hypertrophy
Hemolysis
Vasoconstriction
Immunosuppression
Electrolytes
Prostaglandins
Adrenal Cortex Hormones
Homeostasis
Sodium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Textor, S. C., Canzanello, V. J., Taler, S. J., Wilson, D. J., Schwartz, L. L., Augustine, J. E., ... Burnett, J. C. J. (1994). Cyclosporine-induced hypertension after transplantation. Mayo Clinic Proceedings, 69(12), 1182-1193.

Cyclosporine-induced hypertension after transplantation. / Textor, Stephen C; Canzanello, V. J.; Taler, Sandra J; Wilson, D. J.; Schwartz, L. L.; Augustine, J. E.; Raymer, J. M.; Romero, J. C.; Wiesner, R. H.; Krom, R. A F; Burnett, John C Jr.

In: Mayo Clinic Proceedings, Vol. 69, No. 12, 1994, p. 1182-1193.

Research output: Contribution to journalArticle

Textor, SC, Canzanello, VJ, Taler, SJ, Wilson, DJ, Schwartz, LL, Augustine, JE, Raymer, JM, Romero, JC, Wiesner, RH, Krom, RAF & Burnett, JCJ 1994, 'Cyclosporine-induced hypertension after transplantation', Mayo Clinic Proceedings, vol. 69, no. 12, pp. 1182-1193.
Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE et al. Cyclosporine-induced hypertension after transplantation. Mayo Clinic Proceedings. 1994;69(12):1182-1193.
Textor, Stephen C ; Canzanello, V. J. ; Taler, Sandra J ; Wilson, D. J. ; Schwartz, L. L. ; Augustine, J. E. ; Raymer, J. M. ; Romero, J. C. ; Wiesner, R. H. ; Krom, R. A F ; Burnett, John C Jr. / Cyclosporine-induced hypertension after transplantation. In: Mayo Clinic Proceedings. 1994 ; Vol. 69, No. 12. pp. 1182-1193.
@article{3870a7841e634e189662a71374efb599,
title = "Cyclosporine-induced hypertension after transplantation",
abstract = "Objective: To describe the features and mechanisms of posttransplantation hypertension and suggest appropriate management of the disorder. Design: We review our own experience and reports from the literature on hypertension in cyclosporine A (CSA)-treated transplant recipients. Results: Soon after immunosuppression with CSA and corticosteroids, hypertension develops in most patients who undergo transplantation. The blood pressure increases, which are usually moderate, occur universally because of increased peripheral vascular resistance. Disturbances in circadian patterns of blood pressure lead to loss of the normal nocturnal decline, a feature that magnifies hypertensive target effects. Changes in blood pressure sometimes are severe and associated with rapidly developing target injury, including intracranial hemorrhage, left ventricular hypertrophy, and microangiopathic hemolysis. The complex mechanisms that underlie this disorder include alterations in vascular reactivity that cause widespread vasoconstriction. Vascular effects in the kidney lead to reduced glomerular filtration and impaired sodium excretion. Many of these changes affect local regulation of vascular tone, including stimulation of endothelin and suppression of vasodilating prostaglandins. Effective therapy includes use of vasodilating agents, often calcium channel blocking drugs. Caution must be exercised to avoid interfering with the disposition of CSA or aggravating adverse effects relative to kidney and electrolyte homeostasis. Conclusion: Recognition and treatment of CSA- induced hypertension and vascular injury are important elements in managing the transplant recipient.",
author = "Textor, {Stephen C} and Canzanello, {V. J.} and Taler, {Sandra J} and Wilson, {D. J.} and Schwartz, {L. L.} and Augustine, {J. E.} and Raymer, {J. M.} and Romero, {J. C.} and Wiesner, {R. H.} and Krom, {R. A F} and Burnett, {John C Jr.}",
year = "1994",
language = "English (US)",
volume = "69",
pages = "1182--1193",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "12",

}

TY - JOUR

T1 - Cyclosporine-induced hypertension after transplantation

AU - Textor, Stephen C

AU - Canzanello, V. J.

AU - Taler, Sandra J

AU - Wilson, D. J.

AU - Schwartz, L. L.

AU - Augustine, J. E.

AU - Raymer, J. M.

AU - Romero, J. C.

AU - Wiesner, R. H.

AU - Krom, R. A F

AU - Burnett, John C Jr.

PY - 1994

Y1 - 1994

N2 - Objective: To describe the features and mechanisms of posttransplantation hypertension and suggest appropriate management of the disorder. Design: We review our own experience and reports from the literature on hypertension in cyclosporine A (CSA)-treated transplant recipients. Results: Soon after immunosuppression with CSA and corticosteroids, hypertension develops in most patients who undergo transplantation. The blood pressure increases, which are usually moderate, occur universally because of increased peripheral vascular resistance. Disturbances in circadian patterns of blood pressure lead to loss of the normal nocturnal decline, a feature that magnifies hypertensive target effects. Changes in blood pressure sometimes are severe and associated with rapidly developing target injury, including intracranial hemorrhage, left ventricular hypertrophy, and microangiopathic hemolysis. The complex mechanisms that underlie this disorder include alterations in vascular reactivity that cause widespread vasoconstriction. Vascular effects in the kidney lead to reduced glomerular filtration and impaired sodium excretion. Many of these changes affect local regulation of vascular tone, including stimulation of endothelin and suppression of vasodilating prostaglandins. Effective therapy includes use of vasodilating agents, often calcium channel blocking drugs. Caution must be exercised to avoid interfering with the disposition of CSA or aggravating adverse effects relative to kidney and electrolyte homeostasis. Conclusion: Recognition and treatment of CSA- induced hypertension and vascular injury are important elements in managing the transplant recipient.

AB - Objective: To describe the features and mechanisms of posttransplantation hypertension and suggest appropriate management of the disorder. Design: We review our own experience and reports from the literature on hypertension in cyclosporine A (CSA)-treated transplant recipients. Results: Soon after immunosuppression with CSA and corticosteroids, hypertension develops in most patients who undergo transplantation. The blood pressure increases, which are usually moderate, occur universally because of increased peripheral vascular resistance. Disturbances in circadian patterns of blood pressure lead to loss of the normal nocturnal decline, a feature that magnifies hypertensive target effects. Changes in blood pressure sometimes are severe and associated with rapidly developing target injury, including intracranial hemorrhage, left ventricular hypertrophy, and microangiopathic hemolysis. The complex mechanisms that underlie this disorder include alterations in vascular reactivity that cause widespread vasoconstriction. Vascular effects in the kidney lead to reduced glomerular filtration and impaired sodium excretion. Many of these changes affect local regulation of vascular tone, including stimulation of endothelin and suppression of vasodilating prostaglandins. Effective therapy includes use of vasodilating agents, often calcium channel blocking drugs. Caution must be exercised to avoid interfering with the disposition of CSA or aggravating adverse effects relative to kidney and electrolyte homeostasis. Conclusion: Recognition and treatment of CSA- induced hypertension and vascular injury are important elements in managing the transplant recipient.

UR - http://www.scopus.com/inward/record.url?scp=0027946862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027946862&partnerID=8YFLogxK

M3 - Article

C2 - 7967781

AN - SCOPUS:0027946862

VL - 69

SP - 1182

EP - 1193

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 12

ER -